What are you searching for?

Sign in
Breaking News

Allergan’s RESTASIS Approved with Aptar’s Ophthalmic Squeeze Dispenser

Becomes first FDA-approved multidose delivery system to handle Rx eye treatment formulations without preservatives

By: Kristin Brooks

Managing Editor, Contract Pharma

Aptar Pharma’s preservative-free multidose Ophthalmic Squeeze Dispenser is available for patients in the U.S. for the first time with Allergan’s RESTASIS MULTIDOSE (Cyclosporine Ophthalmic Emulsion) for the treamtent of dry eye. Aptar works closely with Allergan to help improve patient safety, achieve dosing accuracy and maintain product integrity.

Aptar’s Ophthalmic Squeeze Dispenser the first, and only, U.S. FDA- approved multidose delivery system to handle prescription eye treatment formulations without preservatives, which can cause unpleasant and sometimes serious side effects. 

“Our Ophthalmic Squeeze Dispenser technology has been a great success for our customers,” said Salim Haffar, President, Aptar Pharma. “The proven and unrivalled microbiological safety, combined with a precise and reproducible drop ejection allows pharmaceutical customers worldwide to enter into discussions with regulatory agencies such as the FDA.” Mr. Haffar also points out the user-friendliness of the system, “The ergonomic and pocket-size design and the intuitiveness of a squeezable container with a low actuation force certainly contribute to the high levels of acceptance among patients and consumers around the world.” 

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics